Arcosa, Inc. (ACA)
Quantitative Summary
DeterministicAt 28.3x earnings — a 37% discount to the sector average of 44.7x — ACA is in the lower valuation range. Strong operational fundamentals (Piotroski 8/9).
Generated deterministically from quant metrics and financial statements. Not a recommendation.
Algorithmic Teardown
AI-GeneratedArcosa's capital allocation efficiency presents a distinct profile, anchored by an ROIC of 6.2% that falls below the typical threshold for high-quality compounders, suggesting limited ability to generate excess returns over the cost of capital in isolation. The equity generation is driven primarily by operational leverage rather than margin expansion or asset velocity; specifically, a DuPont decomposition reveals that while net margins sit at 7.2%, this performance relies heavily on an equity multiplier of 1.89x, indicating significant financial leverage supports the reported return on equity of 7.9%. Despite these capital efficiency metrics, fundamental integrity appears robust, evidenced by a strong Piotroski F-Score of 8/9 and a negative Beneish M-Score of -2.48, which collectively signal low earnings manipulation risk and stable financial health alongside double-digit revenue growth of 12.2% year-over-year.
Valuation metrics suggest the market is pricing in significant premium expectations relative to historical norms and peer groups, as the current multiple exceeds a sector average P/E of 47.5x. This elevated valuation implies that investors are anticipating sustained high-growth trajectories or superior risk-adjusted returns not yet reflected in the modest ROIC spread. While a DCF model calculates a fair value of $100, providing an anchor for intrinsic worth based on projected cash flows and implied growth assumptions, the gap between current market pricing and this theoretical floor necessitates scrutiny regarding whether consensus estimates adequately capture potential execution risks or if multiple compression is already embedded in today's share price.
From a risk-reward perspective, the neutral insider flow over the last 90 days offers no directional signal from management, creating an information vacuum that contrasts with the otherwise solid fundamental scores. The combination of high leverage driving ROE and sub-par capital efficiency against a rich valuation multiple creates a scenario where downside protection may rely on margin expansion or further revenue acceleration to justify the premium, while upside potential remains contingent on successful navigation of sector-wide headwings without requiring significant balance sheet deleveraging.
Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.
DCF Sandbox
InteractiveSensitivity Matrix
| TG ↓ / WACC → | 8% | 10% | 12% |
|---|---|---|---|
| 2% | $128 | $87 | $62 |
| 3% | $155 | $100 | $70 |
| 4% | $195 | $118 | $79 |
Center = base case. Green = >10% upside, Red = >10% downside vs —.
Pre-computed DCF: WACC=10.0%, terminal growth 3%. Fair value $100 (+0.0%). Not investment advice.
Valuation Context
Price Chart with Moving Averages
Quant Health Deep Dive
Profitability & Value Creation
✅ Conservative payout — room for dividend increases.
DuPont Analysis — ROE Decomposition
Breaking down Return on Equity to see how the company generates its ROE — efficiency, margins, or leverage.
Balance Sheet Health
Earnings Surprise History
EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.
Underwater (Drawdown from Peak)
How far below the all-time high the price has been over time. Deeper = more pain for holders.
Rolling 60-Day Beta vs S&P 500 (VOO)
How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.
Fundamentals
Passive Flow Attribution
ETF Draft EffectWhen investors buy or sell ETFs like SLYG or SPSM, the fund manager is mechanically forced to buy or sell ACA shares regardless of Arcosa, Inc.'s individual fundamentals. We estimate $968M of passive capital is structurally linked to ACA through 8 tracked ETFs. Passive flows have a limited but growing influence on ACA's daily trading dynamics.
Passive exposure = Σ (ETF AUM × stock weight in ETF) across 8 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.
ETF Contagion Visualizer
Simulate a price drop in Arcosa, Inc. to visualize passive redemption contagion across ETFs and collateral stocks.
If Arcosa, Inc. (ACA) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies SEMTECH CORP (SMTC) as the most exposed collateral stock, sharing 3 ETFs with ACA. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.
Contagion model based on shared ETF exposure and constituent weights across 18 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.
ACA Ownership Dynamics
ETFs with Highest ACA Exposure
Float lock-up computed from 18 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).
ACA Capital Efficiency
How efficiently does Arcosa, Inc. convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.
Arcosa, Inc. converts 31% of its EBITDA into free cash flow, a moderate conversion rate — significant EBITDA is consumed by capital expenditures, working capital changes, or interest payments. The 69% reinvestment rate signals aggressive capacity expansion.
Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.
Fails-to-Deliver (FTD) History
SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.
| Date | Failed Shares | Close Price | Notional Value |
|---|---|---|---|
| 2026-05-11 | 6 | $129.94 | $779.64 |
| 2026-05-05 | 69 | $123.19 | $8,500.11 |
| 2026-04-28 | 10,833 | $120.44 | $1.3M |
| 2026-04-14 | 10 | $114.47 | $1,144.7 |
| 2026-04-08 | 42 | $106.21 | $4,460.82 |
| 2026-03-26 | 477 | $106.72 | $50,905.44 |
| 2026-03-16 | 597 | $105.68 | $63,090.96 |
| 2026-02-13 | 29 | $126.72 | $3,674.88 |
| 2026-01-22 | 2,942 | $117.31 | $345,126.02 |
| 2026-01-02 | 7 | $106.32 | $744.24 |
| 2025-11-28 | 4 | $106.42 | $425.68 |
| 2025-11-25 | 7 | $104.64 | $732.48 |
| 2025-11-17 | 3,699 | $100.48 | $371,675.52 |
| 2025-10-29 | 70 | $93.62 | $6,553.4 |
| 2025-10-15 | 47 | $93.01 | $4,371.47 |
| 2025-10-14 | 144 | $90.80 | $13,075.2 |
Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.
Compare ACA to Peers
Quant metrics computed deterministically from financial statements and price data. Updated: N/A.
SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.